Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biohit: Sustainability of turnaround being tested

BIOBVExtensive research2023-07-02 10:00
Inderes
Discuss
Download report (PDF)

Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period. We feel a permanent turnaround of the result is likely thanks to new products, the renewed Chinese distribution agreement and effective implementation of the strategy. We believe that the development of new products and successful commercialization are key to the company's long-term success.

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures2023-06-30

202223e24e
Revenue11.011.312.6
growth-%17.0 %3.2 %11.5 %
EBIT (adj.)1.11.21.6
EBIT-% (adj.)10.3 %10.9 %12.4 %
EPS (adj.)0.040.070.09
Dividend0.000.000.05
Dividend %2.4 %
P/E (adj.)39.330.923.3
EV/EBITDA11.415.012.1

Forum discussions

That’s certainly true. But since there’s hardly any other information available, it raises doubts about where the share is heading—already in...
10/22/2026, 12:29 PM
by Ehemot
1
Yes, there is, roughly a good 30% of the total number of shares. One of that size is most likely preparing for inorganic growth; after all, ...
10/21/2026, 7:52 AM
by Puutaheinää
2
Isn’t there some vague, really massive share issue authorization “in the pipeline” that at least no retail investor knows what it’s going to...
10/21/2026, 7:44 AM
by Ehemot
1
Biohit has dropped rapidly to roughly the level it was at 3 years ago. I find this quite strange considering how the company’s numbers are developing...
10/21/2026, 7:37 AM
by Puutaheinää
5
And here are Antti’s latest comments on Biohit Biohit published the CEO’s Q3 blog post on Wednesday, which provided a qualitative review of ...
10/15/2026, 5:12 AM
by Sijoittaja-alokas
4
A new CEO blog post was published by Biohit today: Biohit Biohit - IR-blogi Biohit Oyj on vuonna 1988 perustettu globaaleilla markkinoilla toimiva...
10/14/2026, 12:46 PM
by Antti Siltanen
9
Here are Antti’s comments on Biohit publishing a scientific review that discusses a two-stage strategy for preventing stomach cancer using GastroPanel...
9/10/2026, 5:01 AM
by Sijoittaja-alokas
7